Biognosys Enters Collaboration with Leading Life Science Company to Advance Next-generation Proteomics
Biognosys, an innovator and leader in next-generation proteomics technology and solutions for life sciences research, announced today that they have entered a collaboration with Evotec, a life science company that discovers, develops, and provides highly effective therapeutics for patients, to advance the adoption of next-generation proteomics in drug discovery and clinical research.
Evotec has been a long-term user of Biognosys’ software and kits within its research. The two companies are now working closely together to integrate Biognosys’ next-generation proteomics data analysis platform in drug discovery and clinical proteomics.
Under the extended partnership, Evotec will continue to utilize Spectronaut, Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics, in its research. The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types.
Additionally, Evotec is implementing Biognosys’ unique workflow for mass spectrometry facility management. This workflow combines Biognosys’ proprietary QuiC software with its patented indexed Retention Time (iRT) technology and iRT Kit to generate near real-time readouts from mass spectrometry instrument raw files for quality control.
The collaboration uniquely combines Evotec’s partnered drug discovery and development business model and focus on data-driven precision medicine, and Biognosys’ expertise and know-how in applying next-generation proteomics to transforming drug discovery and development.
Kristina Beeler, PhD, CBO of Biognosys, comments: “We are excited to deploy the power of proteomics to address some of the key challenges of drug development and work closely with Evotec to de-risk therapeutic assets early on.”
Christoph Schaab, PhD, SVP Head of Proteomics & Metabolomics at Evotec, comments: “Discovery proteomics is increasing its importance to derive functional insights in the early stages of the drug development pipeline. We are thrilled to integrate Biognosys’ proteomics data analysis expertise into Evotec’s pre-clinical and clinical development solutions for the benefit of our biopharma partners.”
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.
About Evotec
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the worldleading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210913005750/en/
Contact information
Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stefanini Group Announces Major 2026 Investment and Expansion in France During Brazil-France Forum27.11.2025 10:00:00 EET | Press release
Stefanini Group, a global tech consulting company with expertise in digital transformation and artificial intelligence solutions, today announces a significant, multi-faceted commitment to the French market. The company plans a major investment and strategic expansion throughout 2026. The announcement is timed to the participation of Marco Stefanini, Founder and Global CEO of Stefanini Group, in the technology panel at the LIDE Brazil–France Forum, scheduled in Paris for November 26–27, 2025. “France is a crucial hub for the next wave of global digital transformation. Our increased investment here reinforces our AI-First methodology for French enterprises, leveraging cutting-edge technology to accelerate their digital journey and drive a new era of efficiency and innovation,” said Marco Stefanini. The company is aiming to substantially strengthen its presence in France through a dual approach: AI-driven organic growth and targeted acquisition. The CEO's visit will culminate with a priv
Hytera Introduces Smart PoC Radios P50E and P60 at PMRExpo 202527.11.2025 10:00:00 EET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, has officially launched its latest smart Push-to-Talk over Cellular (PoC) radios – the P50E and the P60 – at PMRExpo 2025. This launch marks a significant expansion of Hytera’s PoC portfolio, delivering the company’s most robust and comprehensive range of devices to date, offering a wide spectrum of options to meet the growing demand for PoC solutions across all sectors throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126296378/en/ Hytera unveiled new PoC radios P50E & P60 at PMRExpo 2025. Stay Smart and Safe with the P50E Featuring a compact 0.96-inch screen and a keyboard-free design, the P50E embodies the design philosophy of the P5 Series – Where Reliability Meets Simplicity. With the addition of the P50E, the P5 Series – which also includes the P50 and the P50 Pro – now provides users greater flexibility to align
SFI Health™ Reports Promising Results From a Preliminary Study Evaluating the Impact of Long-Chain Polyunsaturated Fatty Acids on Reading and Writing Skills in Children27.11.2025 09:15:00 EET | Press release
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce the publication on Biomedicine of the results of a new study, conducted by the Italian research institute “IRCCS Eugenio Medea” of “La Nostra Famiglia” association, investigating the correlation between long-chain polyunsaturated fatty acids (LCPUFA) and reading and writing abilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126097656/en/ Italian Research Institute "IRCCS Eugenio Medea" of "La Nostra Famiglia". This investigator-initiated trial is part of an ongoing project investigating the efficacy of omega-3 and omega-6 LCPUFA supplementation to enhance the effects of neuropsychological treatment in children diagnosed with developmental dyslexia (DD). LCPUFAs of the omega-3 group, such as EPA and DHA, play essential roles in microglial activity, neuroinflammatory regulation, and synaptic plasticity—pr
WattCycle Unveils 2025 Black Friday Battery Sales with Europe-Wide Savings on LiFePO4 Batteries27.11.2025 08:00:00 EET | Press release
WattCycle today announces the launch of its Europe-wide Black Friday battery deals 2025, offer up to 60% off for LiFePO4 batteries plus an additional 8% discount at checkout with no minimum order value. All EU users are covered by 30 days price protection policy to ensure they secure the best available price during the promotion. Get your Battery Coupon Code: BlackFriday8% Of particular note is the WattCycle 12V 314Ah battery, featured as the most heavily discounted product in the 2025 Black Friday sales. The battery is offered at €489,99 (was €1.299,99), representing a 60% discount. After using the "BlackFriday8%" battery coupon code only €450.79. This battery delivers 4.019Wh of usable energy and engineered with advanced 200A BMS and EV A+ Grade cells rated for 15.000+ cycles, offering a reliable long-term power solution for diverse applications. WattCycle Marine Solution The European boating season underscores the need for dependable, lightweight power. WattCycle 12V 100Ah TM Blueto
JPMorganChase Announces Intention to Build a New Three-Million Sq Ft Landmark Tower in London27.11.2025 08:00:00 EET | Press release
JPMorganChase is proud to announce its intention to build a new three-million square feet tower in London. This transformative project would enable additional capacity for the firm to grow by creating a world-class workplace for up to 12,000employees, further strengthening London’s position as a global financial hub. The plans are subject to a continuing positive business environment in the UK and the receipt of the necessary approvals and agreements at a national and local level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126040802/en/ Artist's impression: The view from JPMorganChase's Riverside office Serving as the firm’s principal headquarters in the UK and its most significant presence in EMEA, the building would be situated on the Riverside development in Canary Wharf. The plans will provide employees and clients with a first-class working environment against a backdrop of uninterrupted views across the River Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom